Tag Archives: MASH

Screening for fatty liver disease in patients with diabetes is no longer limited to identifying elevated liver enzymes or calculating a fibrosis score during an annual visit. Instead, clinicians are entering an era where diabetes care and hepatology increasingly overlap, especially as metabolic dysfunction-associated steatotic liver disease, or MASLD, becomes …

The rising interest in GLP‑1 MASLD MASH treatment has transformed how clinicians view metabolic therapies for patients with type 2 diabetes and obesity. While GLP‑1 receptor agonists have long been recognized for their glucose-lowering and weight-loss effects, they now offer potential for improving liver outcomes, especially in individuals with metabolic …